CytoDyn’s COVID-19 Long-Hauler’s Trial Closed as Enrollment Exceeds Goals
April 08, 2021 17:41 ET
|
CytoDyn Inc.
VANCOUVER, Washington, April 08, 2021 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY), (“CytoDyn” or the “Company"), a late-stage biotechnology company developing leronlimab (PRO 140), a CCR5...
CytoDyn Providing Leronlimab to a Philippine Hospital for 28 More COVID-19 Patients under Compassionate Special Permit (CSP)
April 07, 2021 16:01 ET
|
CytoDyn Inc.
CytoDyn also negotiating the potential future delivery of 100,000 vials to the Philippines for additional CSP use VANCOUVER, Washington, April 07, 2021 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB:...
CytoDyn Signs Exclusive Supply and Distribution Agreement with Biomm S.A. in Brazil for COVID-19 and All Other Leronlimab Indications
April 07, 2021 06:00 ET
|
CytoDyn Inc.
VANCOUVER, Washington, April 07, 2021 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY), (“CytoDyn” or the “Company"), a late-stage biotechnology company developing leronlimab (PRO 140), a CCR5...
CytoDyn Reschedules Webcast from April 6 to April 7
April 05, 2021 16:29 ET
|
CytoDyn Inc.
VANCOUVER, Washington, April 05, 2021 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY), (“CytoDyn” or the “Company"), a late-stage biotechnology company developing Vyrologix™ (leronlimab-PRO 140), a...
CytoDyn Completes $28.5 Million Convertible Note Financing with Conversion Rate at $10.00 Per Share Without Warrants to Accelerate Manufacturing of Leronlimab Inventory
April 05, 2021 06:05 ET
|
CytoDyn Inc.
VANCOUVER, Washington, April 05, 2021 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY), (“CytoDyn” or the “Company"), a late-stage biotechnology company developing leronlimab (PRO 140), a CCR5...
First Compassionate Special Permit (CSP) Patient in Philippines Improved Significantly 35 hours After First Injection of Leronlimab and Released 3 Days Later
April 05, 2021 06:00 ET
|
CytoDyn Inc.
VANCOUVER, Washington, April 05, 2021 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY), (“CytoDyn” or the “Company"), a late-stage biotechnology company developing Vyrologix™ (leronlimab-PRO 140), a...
CytoDyn to Hold Webcast on April 6 to Provide a Full Update on Its Activities
April 01, 2021 06:15 ET
|
CytoDyn Inc.
VANCOUVER, Washington, April 01, 2021 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY), (“CytoDyn” or the “Company"), a late-stage biotechnology company developing Vyrologix™ (leronlimab-PRO 140), a...
CytoDyn Files New Protocol with U.S. FDA for 4 Doses of Leronlimab for Critically Ill COVID-19 Patients with the Objective to Duplicate or Surpass 82% Survival Benefit with P-Value of 0.0233 Originally Achieved from Two Weeks of Treatment in CD12 Trial With 2 Doses
April 01, 2021 06:00 ET
|
CytoDyn Inc.
Trial commencement will be expedited by enrolling patients in Brazil, U.K., and Canada while immediate EUA requests are pursued in multiple countries VANCOUVER, Washington, April 01, 2021 (GLOBE...
CytoDyn’s Leronlimab Decreased Mortality at 14 Days by 82% With Statistically Significant P-Value of 0.0233 Amongst Critically Ill COVID-19 Patients
March 30, 2021 06:00 ET
|
CytoDyn Inc.
Clinical outcome improvement (based on ordinal scale) with leronlimab at day 14 was 400% better than placebo arm with p-value of 0.021 VANCOUVER, Washington, March 30, 2021 (GLOBE NEWSWIRE) --...
Remarkable Turnaround Following Leronlimab Treatment in Critically Ill COVID-19 Patient After 84 days on ECMO; Case Study Published in Journal of Translational Autoimmunity
March 29, 2021 06:15 ET
|
CytoDyn Inc.
CD12 trial results also indicated that five out of six patients on ECMO recovered VANCOUVER, Washington, March 29, 2021 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY), ("CytoDyn" or the...